Literature DB >> 21512413

Pulmonary hypertension in patients with neurofibromatosis type I.

David Montani1, Florence Coulet, Barbara Girerd, Mélanie Eyries, Emmanuel Bergot, Hervé Mal, Giuseppina Biondi, Claire Dromer, Thomas Hugues, Charles Marquette, Caroline O'Connell, Dermot S O'Callaghan, Laurent Savale, Xavier Jaïs, Peter Dorfmüller, Hugues Begueret, Laurent Bertoletti, Olivier Sitbon, Christine Bellanné-Chantelot, Gérard Zalcman, Gérald Simonneau, Marc Humbert, Florent Soubrier.   

Abstract

Neurofibromatosis type I (NF1) is a rare genetic disease caused by mutations in the NF1 gene, which codes for tumor suppressor neurofibromin. NF1 is transmitted as an autosomal dominant and fully penetrant trait with no sex predominance. Precapillary pulmonary hypertension (PH) is a severe complication of NF1, initially described in patients with advanced parenchymal lung disease, which may complicate the course of NF1. We conducted this study to describe clinical, functional, radiologic, and hemodynamic characteristics and outcome of patients with NF1-associated PH. We identified 8 new cases of NF1-associated PH in patients carrying a NF1 gene mutation. No bone morphogenic protein receptor 2 (BMPR2) point mutation or large size rearrangements were identified. Seven female patients and 1 male patient were reported, suggesting a possible female predominance. PH occurred late in the course of the disease (median age, 62 yr; range, 53-68 yr). Dyspnea and signs of right heart failure were the major symptoms leading to the diagnosis of PH. At diagnosis, patients had severe hemodynamic impairment with low cardiac index (median, 2.3 L/min per m2; range, 1.9-4.7) and elevated indexed pulmonary vascular resistance (median, 15.1 mm Hg/L/min per m2; range, 4.5-25.9). All patients were in New York Heart Association functional class III with severe exercise limitation (median 6-min walk distance, 180 m; range, 60-375 m). Most patients had associated parenchymal lung disease, but some had no or mild lung involvement with disproportionate pulmonary vascular disease. Overall, the impact of PH therapy was limited and outcomes were poor. In conclusion, PH represents a rare but severe complication of NF1, characterized by female predominance, late onset in the course of NF1, and severe functional and hemodynamic impairment. Because of poor outcome and limited impact of specific PH therapy, eligible patients require early referral for lung transplantation. Further studies are needed to better understand the pathophysiology and the role, if any, of neurofibromin in NF1-associated PH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512413     DOI: 10.1097/MD.0b013e31821be2b7

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  14 in total

1.  Type 1 neurofibromatosis and pulmonary hypertension: a report of two cases and a review.

Authors:  Amit Malviya; Sundeep Mishra; Shyam S Kothari
Journal:  Heart Asia       Date:  2012-01-01

2.  Increased risk of breast cancer in women with NF1.

Authors:  Sara Aileen Madanikia; Amanda Bergner; Xiaobu Ye; Jaishri O'Neill Blakeley
Journal:  Am J Med Genet A       Date:  2012-11-19       Impact factor: 2.802

Review 3.  Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.

Authors:  Jaishri O Blakeley; Scott R Plotkin
Journal:  Neuro Oncol       Date:  2016-02-06       Impact factor: 12.300

Review 4.  Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management.

Authors:  Fatima A Ballout; Ahmad S Manshad; Tochukwu M Okwuosa
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-06

5.  Neurofibromatosis-associated pulmonary hypertension: an ominous duo.

Authors:  Sónia Gomes Coelho; Maria José Loureiro
Journal:  BMJ Case Rep       Date:  2020-07-13

Review 6.  Pulmonary arterial hypertension.

Authors:  David Montani; Sven Günther; Peter Dorfmüller; Frédéric Perros; Barbara Girerd; Gilles Garcia; Xavier Jaïs; Laurent Savale; Elise Artaud-Macari; Laura C Price; Marc Humbert; Gérald Simonneau; Olivier Sitbon
Journal:  Orphanet J Rare Dis       Date:  2013-07-06       Impact factor: 4.123

7.  Atrial septostomy and disease targeting therapy in pulmonary hypertension secondary to neurofibromatosis.

Authors:  George Giannakoulas; Panagiotis Savvoulidis; Vasilios Grosomanidis; Sophia-Anastasia Mouratoglou; Haralambos Karvounis; Stavros Hadjimiltiades
Journal:  BMC Pulm Med       Date:  2016-12-07       Impact factor: 3.317

8.  [Spontaneous hemothorax: a rare complication of neurofibromatosis type 1].

Authors:  Soumia Fdil; Saad Bouchikhi; Jamal-Eddine Bourkadi
Journal:  Pan Afr Med J       Date:  2017-09-27

9.  Severe dyspnea in a patient with neurofibromatosis type 1.

Authors:  P B Poble; J C Dalphin; B Degano
Journal:  Respir Med Case Rep       Date:  2017-06-17

10.  Interstitial lung disease and pre-capillary pulmonary hypertension in neurofibromatosis type 1.

Authors:  Daniela Rodrigues; Hugo Oliveira; Carina Andrade; Luísa Carvalho; Susana Guimarães; Conceição Souto Moura; Ana Paula Vaz
Journal:  Respir Med Case Rep       Date:  2018-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.